MCID: HYP030
MIFTS: 40

Hypoactive Sexual Desire Disorder

Categories: Mental diseases

Aliases & Classifications for Hypoactive Sexual Desire Disorder

MalaCards integrated aliases for Hypoactive Sexual Desire Disorder:

Name: Hypoactive Sexual Desire Disorder 12 76 15 73
Sexual Dysfunctions, Psychological 44
Lack or Loss of Sexual Desire 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13868
ICD10 33 F52.0
ICD9CM 35 302.71
MeSH 44 D020018
NCIt 50 C94337
UMLS 73 C0020594

Summaries for Hypoactive Sexual Desire Disorder

MalaCards based summary : Hypoactive Sexual Desire Disorder, also known as sexual dysfunctions, psychological, is related to depression and schizoid personality disorder. An important gene associated with Hypoactive Sexual Desire Disorder is CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1), and among its related pathways/superpathways are Monoamine GPCRs and Serotonergic synapse. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and testes, and related phenotypes are Decreased viability after Maraba virus infection and Decreased viability after Maraba virus infection

Wikipedia : 76 Hypoactive sexual desire disorder (HSDD) or inhibited sexual desire (ISD) is considered a sexual... more...

Related Diseases for Hypoactive Sexual Desire Disorder

Diseases related to Hypoactive Sexual Desire Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 depression 30.3 HTR1A HTR2A
2 schizoid personality disorder 10.3 HTR1A HTR2A
3 substance-induced psychosis 10.3 HTR1A HTR2A
4 periodic limb movement disorder 10.2 HTR1A HTR2A
5 drug-induced mental disorder 10.2 HTR1A HTR2A
6 drug psychosis 10.2 HTR1A HTR2A
7 borderline personality disorder 10.2 HTR1A HTR2A
8 serotonin syndrome 10.2 HTR1A HTR2A
9 androgen insensitivity, partial 10.2 CYP19A1 SHBG
10 estrogen excess 10.2 CYP19A1 SHBG
11 alopecia, androgenetic, 1 10.2 CYP19A1 SHBG
12 bipolar i disorder 10.2 HTR1A HTR2A
13 androgenic alopecia 10.2 CYP19A1 SHBG
14 mental depression 10.2 HTR1A HTR2A
15 complete androgen insensitivity syndrome 10.2 CYP19A1 SHBG
16 sex differentiation disease 10.2 CYP19A1 SHBG
17 generalized anxiety disorder 10.1 HTR1A HTR2A
18 gynecomastia 10.1 CYP19A1 SHBG
19 personality disorder 10.1 HTR1A HTR2A
20 breast cancer 10.1
21 aging 10.1
22 transsexuality 10.1
23 transsexualism 10.1
24 inhibited female orgasm 10.1
25 anovulation 10.1 CYP19A1 SHBG
26 sexual disorder 10.1 HTR1A SHBG
27 female reproductive system disease 10.1 CYP19A1 SHBG
28 disease of mental health 10.1 HTR1A HTR2A
29 hyperandrogenism 10.1 CYP19A1 SHBG
30 reproductive system disease 10.0 CYP19A1 SHBG
31 cryptorchidism, unilateral or bilateral 10.0 CYP19A1 SHBG
32 premature ovarian failure 1 10.0 CYP19A1 SHBG
33 ovarian disease 10.0 CYP19A1 SHBG
34 polycystic ovary syndrome 9.9 CYP19A1 SHBG
35 mood disorder 9.9 HTR1A HTR2A
36 psychotic disorder 9.9 HTR1A HTR2A
37 obsessive-compulsive disorder 9.8 HTR1A HTR2A
38 anxiety 9.7 HTR1A HTR2A
39 psychosexual disorder 9.5 HTR1A HTR2A SHBG
40 panic disorder 9.4 HTR1A HTR2A
41 bipolar disorder 9.4 HTR1A HTR2A SHBG

Graphical network of the top 20 diseases related to Hypoactive Sexual Desire Disorder:



Diseases related to Hypoactive Sexual Desire Disorder

Symptoms & Phenotypes for Hypoactive Sexual Desire Disorder

GenomeRNAi Phenotypes related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability after Maraba virus infection GR00252-A-1 9.28 CYP19A1 HTR2A
2 Decreased viability after Maraba virus infection GR00252-A-2 9.28 AP1G1 CYP19A1 SHBG
3 Decreased viability after Maraba virus infection GR00252-A-3 9.28 AP1G1 CYP19A1 HTR2A SHBG

Drugs & Therapeutics for Hypoactive Sexual Desire Disorder

Drugs for Hypoactive Sexual Desire Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
3
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1 315-37-7 9416
4
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 5949-44-0
5
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
6 Anabolic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 insulin Phase 4
13 Insulin, Globin Zinc Phase 4
14 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1
15 Estrogens Phase 4,Phase 3,Phase 1,Not Applicable
16 Progestins Phase 4
17 Contraceptive Agents Phase 4,Not Applicable
18 Contraceptives, Oral Phase 4
19 Contraceptives, Oral, Combined Phase 4
20 Tribulus Nutraceutical Phase 4
21
Bupropion Approved Phase 2, Phase 3,Phase 1 34841-39-9, 34911-55-2 444
22
Dopamine Approved Phase 2, Phase 3,Phase 1 51-61-6, 62-31-7 681
23
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3,Not Applicable 53-43-0 9860744
24 Adjuvants, Immunologic Phase 3,Not Applicable
25 Adrenocorticotropic Hormone Phase 3
26 alpha-MSH Phase 3,Phase 2 581-05-5
27 beta-endorphin Phase 3
28 Melanocyte-Stimulating Hormones Phase 3
29 Antidepressive Agents Phase 2, Phase 3,Phase 1
30 Antidepressive Agents, Second-Generation Phase 2, Phase 3,Phase 1
31 Cytochrome P-450 CYP2D6 Inhibitors Phase 2, Phase 3,Phase 1
32 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3,Phase 1
33 Dopamine Agents Phase 2, Phase 3,Phase 1
34 Dopamine Uptake Inhibitors Phase 2, Phase 3,Phase 1
35 Neurotransmitter Agents Phase 2, Phase 3,Phase 1
36 Neurotransmitter Uptake Inhibitors Phase 2, Phase 3,Phase 1
37 Psychotropic Drugs Phase 2, Phase 3,Phase 1
38 DHEA (Dehydroepiandrosterone) Nutraceutical Phase 3,Not Applicable
39
Buspirone Approved, Investigational Phase 2 36505-84-7 2477
40
Trazodone Approved, Investigational Phase 1, Phase 2 19794-93-5 5533
41
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
42
Paroxetine Approved, Investigational Phase 2 61869-08-7 43815
43
Sertraline Approved Phase 2 79617-96-2 68617
44
Ethanol Approved Phase 2 64-17-5 702
45
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
46
Methadone Approved Phase 2 76-99-3 4095
47
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
48 Anti-Anxiety Agents Phase 2
49 Central Nervous System Depressants Phase 2
50 Serotonin Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Testosterone Patch's Effects on the Cardiovascular System and Libido Unknown status NCT01208038 Phase 4 Intrinsa Transdermal testosterone patch
2 Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT01975649 Phase 4 Tribulus Terrestris
3 Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder Completed NCT01971099 Phase 4 tribulus terrestris
4 Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women Recruiting NCT02968342 Phase 4
5 Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy Recruiting NCT02714049 Phase 4 flibanserin
6 Oral Contraceptive Therapy and Sexuality Recruiting NCT02613039 Phase 4 Combined Estrogen-Progestin Oral Contraceptives
7 Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) Completed NCT01235754 Phase 3 transdermal testosterone gel 1%;placebo gel
8 Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women Completed NCT00612742 Phase 3 testosterone gel;placebo gel
9 Testosterone in Female Hypoactive Sexual Desire Disorder Completed NCT00140153 Phase 3 testosterone gel (Androgel)
10 Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Completed NCT00657501 Phase 3 testosterone gel;placebo gel
11 Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Completed NCT00613002 Phase 3 testosterone gel;placebo gel
12 Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women Completed NCT00467259 Phase 3 Testosterone Transdermal System;Placebo patch
13 Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen Completed NCT00384046 Phase 3 Testosterone;Placebo
14 Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT00996164 Phase 3 Flibanserin;Placebo
15 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT00360529 Phase 3 flibanserin
16 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension Completed NCT02338960 Phase 3 Bremelanotide;Placebo
17 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension Completed NCT02333071 Phase 3 bremelanotide
18 Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido Completed NCT00338312 Phase 3 Testosterone Transdermal System;Placebo patch
19 Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido Completed NCT00331214 Phase 3 Testosterone Transdermal System;placebo patch
20 Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido Completed NCT00331123 Phase 3 Testosterone Transdermal System;Placebo
21 Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido Completed NCT00349791 Phase 3 Testosterone Transdermal System;Placebo patch
22 Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women Completed NCT00996372 Phase 3 flibanserin;placebo
23 Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT00360555 Phase 3 flibanserin;flibanserin 50mg;flibanserin 100mg;placebo
24 Flibanserin Versus Placebo in Premenopausal Women With HSDD Completed NCT00491829 Phase 3 50 mg qhs;100 mg;placebo
25 Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido Completed NCT00131495 Phase 3 Testosterone (transdermal patches);Placebo patch
26 Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder Completed NCT00601367 Phase 3 flibanserin flexible dose
27 Female Orgasmic Disorder (FOD) and Wellbutrin XL Completed NCT00248209 Phase 2, Phase 3 Wellbutrin XL
28 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA Completed NCT00360243 Phase 3 flibanserin;flibanserin;flibanserin;placebo
29 Zestra in Women With Mixed Sexual Dysfunction Completed NCT00118495 Phase 3 Non-prescription Zestra(TM): patented formulation
30 Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) Recruiting NCT03287232 Phase 3 Placebo Vaginal Insert;Prasterone 6.5 mg (0.50%) Vaginal Insert
31 BP101 for Adults With Female Sexual Dysfunction Recruiting NCT03463707 Phase 3 BP101;Placebo
32 Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America Terminated NCT01057901 Phase 3 Flibanserin;Placebo
33 A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Terminated NCT01103362 Phase 3 flibanserin
34 A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD). Terminated NCT00441558 Phase 3 Flibanserin
35 Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems Completed NCT01743235 Phase 2 Placebo;Testosterone;Buspirone hydrochloride
36 Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT02101203 Phase 2 Placebo;0.5 mgTestosterone + 10 mg Buspirone
37 Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder Completed NCT01382719 Phase 2 bremelanotide
38 Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety Completed NCT01857596 Phase 1, Phase 2 bupropion, Lorexys low-dose, Lorexys moderate-dose
39 The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause Completed NCT02419209 Phase 2
40 Lybrido for Female Sexual Dysfunction Completed NCT01432665 Phase 2 Placebo;Sildenafil;Testosterone
41 Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire Completed NCT03080298 Phase 2 BP101;Placebo
42 Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction Completed NCT00034021 Phase 2 Ginkgo Biloba
43 Safety Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women Completed NCT02215434 Phase 2 Biolipid B2 (blanked/placebo);Testosterone, Transdermal, Behavior
44 Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men Recruiting NCT02593396 Phase 2 Bupropion hydrochloride sustained-release;placebo
45 Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Completed NCT01188603 Phase 1 flibanserin 100 mg dose every evening
46 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers Active, not recruiting NCT03102489 Phase 1 BP101;Placebo
47 A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa® Terminated NCT01096329 Phase 1 Testosterone Spray 5% and 1%;Intrinsa® Patch and Testosterone Spray 5%;Intrinsa® Patch and Testosterone Spray 1%
48 Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder Unknown status NCT00916396 Not Applicable Dehydroepiandrosterone;placebo
49 Acupuncture for Sexual Dysfunction Completed NCT02070029 Not Applicable
50 Stress Hormones, Mood and Women's Sexual Desire (MODEST) Completed NCT01702818

Search NIH Clinical Center for Hypoactive Sexual Desire Disorder

Cochrane evidence based reviews: sexual dysfunctions, psychological

Genetic Tests for Hypoactive Sexual Desire Disorder

Anatomical Context for Hypoactive Sexual Desire Disorder

MalaCards organs/tissues related to Hypoactive Sexual Desire Disorder:

41
Brain, Liver, Testes

Publications for Hypoactive Sexual Desire Disorder

Articles related to Hypoactive Sexual Desire Disorder:

(show top 50) (show all 186)
# Title Authors Year
1
Treatments for Hypoactive Sexual Desire Disorder (HSDD) and the Pursuit of Sexual Health for Women amidst Inglorious Rhetoric. ( 29914753 )
2018
2
Managing the Hypoactive Sexual Desire Disorder in Women. ( 29545004 )
2018
3
Re: Men's Sexual Response to Female Partner's Intranasal Oxytocin Administration for Hypoactive Sexual Desire Disorder: An Open Prospective Cohort Study. ( 29310164 )
2018
4
The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. ( 29545008 )
2018
5
Evaluation and Management of Hypoactive Sexual Desire Disorder. ( 29523488 )
2018
6
Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study. ( 29502984 )
2018
7
Ignorance Is Not Bliss: If We Don't Understand Hypoactive Sexual Desire Disorder, How Can Flibanserin Treat It? Commentary. ( 29396022 )
2018
8
Assessment of Sexual Desire for Clinical Trials of Women With Hypoactive Sexual Desire Disorder: Measures, Desire-Related Behavior, and Assessment of Clinical Significance. ( 29371145 )
2018
9
Flibanserin for hypoactive sexual desire disorder in premenopausal women. ( 29846316 )
2018
10
The characteristics of hypoactive sexual desire disorder in Korean women who visited a community-based gynaecology hospital for sexual dysfunction. ( 29433404 )
2018
11
Has flibanserin revolutionized the treatment of hypoactive sexual desire disorder or is there still room for more effective therapeutics? ( 29488405 )
2018
12
Transdermal Testosterone in Female Hypoactive Sexual Desire Disorder: A Rapid Qualitative Systematic Review Using Grading of Recommendations Assessment, Development and Evaluation. ( 29868302 )
2018
13
Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. ( 27916394 )
2017
14
Metacognitive Therapy Trial for Hypoactive Sexual Desire Disorder Breaks the Mold. ( 29198515 )
2017
15
A Practical Approach to Managing Hypoactive Sexual Desire Disorder in Women with Diabetes. ( 28918588 )
2017
16
Efficacy of metacognitive therapy for hypoactive sexual desire disorder among Iranian couples. ( 28337949 )
2017
17
Re: Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. ( 29370613 )
2017
18
Men's sexual response to female partner's intranasal oxytocin administration for hypoactive sexual desire disorder: an open prospective cohort study. ( 28189292 )
2017
19
Re: Men's Sexual Response to Female Partner's Intranasal Oxytocin Administration for Hypoactive Sexual Desire Disorder: An Open Prospective Cohort Study. ( 29370616 )
2017
20
Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study. ( 28583342 )
2017
21
Neuroimaging of Female Sexual Desire and Hypoactive Sexual Desire Disorder. ( 28865901 )
2017
22
New developments in the treatment of hypoactive sexual desire disorder - a focus on Flibanserin. ( 28442935 )
2017
23
Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis. ( 28817365 )
2017
24
Efficacy of Tribulus Terrestris for the treatment of premenopausal women with hypoactive sexual desire disorder: a randomized double-blinded, placebo-controlled trial. ( 29172782 )
2017
25
Role of hormones in hypoactive sexual desire disorder and current treatment. ( 29278235 )
2017
26
Flibanserin for hypoactive sexual desire disorder: place in therapy. ( 28203348 )
2017
27
Women With Hypoactive Sexual Desire Disorder versus Sexual Interest/Arousal Disorder: An Empirical Test of Raising the Bar. ( 29095039 )
2017
28
Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options. ( 29198512 )
2017
29
Flibanserin Efficacy and Safety in Premenopausal Women With Generalized Acquired Hypoactive Sexual Desire Disorder. ( 28666836 )
2017
30
What Sexual Behaviors Relate to Decreased Sexual Desire in Women? A Review and Proposal for End Points in Treatment Trials for Hypoactive Sexual Desire Disorder. ( 28041924 )
2016
31
FDA Approval of Flibanserin--Treating Hypoactive Sexual Desire Disorder. ( 26649985 )
2016
32
Acupuncture in Premenopausal Women With Hypoactive Sexual Desire Disorder: A Prospective Cohort Pilot Study. ( 27033339 )
2016
33
Flibanserin: A Novel, Nonhormonal Agent for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women. ( 26873507 )
2016
34
Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis. ( 26927498 )
2016
35
Flibanserin Ineffective for Hypoactive Sexual Desire Disorder in Women. ( 27583427 )
2016
36
Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder in Premenopausal Women. ( 27175717 )
2016
37
Hypoactive Sexual Desire Disorder: A Review of Epidemiology, Biopsychology, Diagnosis, and Treatment. ( 27872021 )
2016
38
Flibanserin for Treating Hypoactive Sexual Desire Disorder. ( 27152308 )
2016
39
Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. ( 27916205 )
2016
40
Efficacy of Tribulus terrestris for the treatment of hypoactive sexual desire disorder in postmenopausal women: a randomized, double-blinded, placebo-controlled trial. ( 27760089 )
2016
41
Psychometric Properties of the Sexual Interest and Desire Inventory-Female for Diagnosis of Hypoactive Sexual Desire Disorder: The Persian Version. ( 28050188 )
2016
42
First Pharmacological Therapy for Hypoactive Sexual Desire Disorder in Premenopausal Women: Flibanserin. ( 26692273 )
2016
43
Systematic Review and Meta-analysis of Flibanserin's Effects and Adverse Events in Women with Hypoactive Sexual Desire Disorder. ( 27784209 )
2016
44
Re: Psychological Treatment Trials for Hypoactive Sexual Desire Disorder: A Sexual Medicine Critique and Perspective. ( 27186767 )
2016
45
Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis. ( 26745616 )
2015
46
Editorial Comment on "Psychology Treatment Trials for Hypoactive Sexual Desire Disorder: A Sexual Medicine Critique and Perspective". ( 26632093 )
2015
47
Hypoactive sexual desire disorder: inventing a disease to sell low libido. ( 26124287 )
2015
48
Validation of the Swedish version of the female sexual function Index (FSFI) in women with hypoactive sexual desire disorder. ( 25487161 )
2015
49
Hypoactive sexual desire disorder caused by antiepileptic drugs. ( 26157303 )
2015
50
Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. ( 25659981 )
2015

Variations for Hypoactive Sexual Desire Disorder

Expression for Hypoactive Sexual Desire Disorder

Search GEO for disease gene expression data for Hypoactive Sexual Desire Disorder.

Pathways for Hypoactive Sexual Desire Disorder

Pathways related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.22 HTR1A HTR2A
2 11.01 HTR1A HTR2A
3 10.07 HTR1A HTR2A

GO Terms for Hypoactive Sexual Desire Disorder

Biological processes related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.37 HTR1A HTR2A
2 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.32 HTR1A HTR2A
3 regulation of behavior GO:0050795 9.26 HTR1A HTR2A
4 behavior GO:0007610 9.16 HTR1A HTR2A
5 regulation of hormone secretion GO:0046883 8.96 HTR1A HTR2A
6 serotonin receptor signaling pathway GO:0007210 8.62 HTR1A HTR2A

Molecular functions related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.37 CYP19A1 CYP4F3
2 monooxygenase activity GO:0004497 9.32 CYP19A1 CYP4F3
3 oxygen binding GO:0019825 9.26 CYP19A1 CYP4F3
4 neurotransmitter receptor activity GO:0030594 9.16 HTR1A HTR2A
5 G-protein coupled serotonin receptor activity GO:0004993 8.96 HTR1A HTR2A
6 serotonin binding GO:0051378 8.62 HTR1A HTR2A

Sources for Hypoactive Sexual Desire Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....